Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Esoxybutynin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 6/20 | 1.00 |
| ▸ | CHRM3 known ✓ | P20309 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aroxybutynin SCHEMBL25880 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL2992 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL1560964 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL7895841 | 0.99 | CHRM2 (0.98) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL8019436 | 0.99 | MEN1 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL25751 | 0.99 | MEN1 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL19816026 | 0.99 | CHRM2 (0.98) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL4606219 | 0.99 | CHRM2 (0.98) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL5494388 | 0.99 | MEN1 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL7557853 | 0.99 | CHRM2 (0.98) | CHRM2CHRM1CHRM4CHRM3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 537 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083709-A1 | COMBINATION PHARMACOLOGICAL INTERVENTIONS FOR MULTIPLE MECHANISMS OF OBSTRUCTIVE SLEEP APNEA | APNIMED INC DELAWARE (US) | 2026-03-26 | — | — | US | claimed |
| US-20250325510-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APRIMED INC DELAWARE (US) | 2025-10-23 | — | — | US | claimed |
| US-20250114321-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) | 2025-04-10 | — | — | US | claimed |
| US-20220362221-A1 | COMBINATION PHARMACOLOGICAL INTERVENTIONS FOR MULTIPLE MECHANISMS OF OBSTRUCTIVE SLEEP APNEA | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2022-11-17 | — | — | US | claimed |
| US-20210401790-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) | 2021-12-30 | — | — | US | claimed |
| EP-3873454-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) (US) | 2021-09-08 | — | — | EP | claimed |
| CN-112930179-A | Methods and compositions for treating sleep apnea | 爱普宁公司(特拉华) | 2021-06-08 | — | — | CN | claimed |
| US-10383510-B2 | Implant with high vapor pressure medium | SOLACE THERAPEUTICS, INC. (US) | 2019-08-20 | — | — | US | claimed |
| EP-2515946-B1 | NANOCONJUGATES AND NANOCONJUGATE FORMULATIONS | UNIV ILLINOIS (US) | 2019-05-22 | — | — | EP | claimed |
| WO-2018126127-A1 | COMPOSITION OF MATTER AND USE THEREOF FOR PREVENTING AND TREATING MOTION SICKNESS | GT BIOPHARMA, INC. (US) | 2018-07-05 | — | — | WO | claimed |
| EP-0806948-B1 | TREATING URINARY INCONTINENCE USING (S)-OXYBUTYNIN AND (S)-DESETHYLOXYBUTYNIN | SEPRACOR INC (US) | 2000-09-13 | — | — | EP | claimed |
| WO-2000023414-A2 | SYNTHESIS OF OPTICALLY ACTIVE CYCLOHEXYLPHENYLGLYCOLIC ACID AND ITS ESTERS | SEPRACOR INC. (US) | 2000-04-27 | — | — | WO | claimed |
| EP-0914113-A1 | TREATING URINARY INCONTINENCE USING (S)-OXYBUTYNIN AND (S)-DESETHYLOXYBUTYNIN | SEPRACOR, INC. (US) | 1999-05-12 | — | — | EP | claimed |
| US-5736577-A | Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin | SEPRACOR, INC. (US) | 1998-04-07 | — | — | US | claimed |
| WO-1998000126-A1 | TREATING URINARY INCONTINENCE USING (S)-OXYBUTYNIN AND (S)-DESETHYLOXYBUTYNIN | SEPRACOR, INC. (US) | 1998-01-08 | — | — | WO | claimed |
| EP-0806948-A1 | TREATING URINARY INCONTINENCE USING (S)-OXYBUTYNIN AND (S)-DESETHYLOXYBUTYNIN | SEPRACOR, INC. (US) | 1997-11-19 | — | — | EP | claimed |
| WO-1996023492-A1 | TREATING URINARY INCONTINENCE USING (S)-OXYBUTYNIN AND (S)-DESETHYLOXYBUTYNIN | SEPRACOR, INC. (US) | 1996-08-08 | — | — | WO | claimed |
| EP-0721349-A1 | MONOGLYCERIDE/LACTATE ESTER PERMEATION ENHANCER FOR OXYBUTYNIN | ALZA CORPORATION (US) | 1996-07-17 | — | — | EP | claimed |
| US-5532278-A | SIDE EFFECT REDUCTION | SEPRACOR, INC. (US) | 1996-07-02 | — | — | US | claimed |
| WO-1995009007-A1 | MONOGLYCERIDE/LACTATE ESTER PERMEATION ENHANCER FOR OXYBUTYNIN | ALZA CORPORATION (US) | 1995-04-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083709-A1 | COMBINATION PHARMACOLOGICAL INTERVENTIONS FOR MULTIPLE MECHANISMS OF OBSTRUCTIVE SLEEP APNEA | CHRNA2, CHRNA3, ADRA2B | CHRM2 37/4885CHRM3 27/4885CHRM1 106/4885 |
| US-20250114321-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | HCRTR2, CHRM3, CHRM2 | CHRM2 3/4885CHRM3 2/4885CHRM1 35/4885 |
| US-20250325510-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | HCRTR2, CHRM3, CHRM2 | CHRM2 3/4885CHRM3 2/4885CHRM1 35/4885 |
| US-20210401790-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | HCRTR2, CHRM3, CHRM2 | CHRM2 3/4885CHRM3 2/4885CHRM1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.